AdvanCell
6 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- $218Msold on Form D
Filed a Form D on 30 Jun 2026: $218M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
A company that just raised has fresh capital, a new board and new vendors to choose.
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 9 directorsboard
9 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
Financing history
- Jun 30, 2026Form D equity offering · $218M (form d sold) · 41 investorsFact Form D · “AdvanCell, Inc. filed Form D: $218,333,294 sold of $315,000,000, Biotechnology”
Who would invest
How comparable investors are foundComparable investors backed two or more of the companies this company’s own investors also back. Broader fit co-invested two or more times with them and dated a new company in the last 12 months. Each reason is a fact on record: a shared company, a co-investment count, a dated deal, a stage or round size it has joined. A shared sector alone never puts a firm here. Nothing is a prediction that a firm will invest.Already invested
1 investor on record- Catalio Capital Management, LP portfolio listing Fact cataliocapital.com
Strong comparable investors
8 firmsFirms that backed two or more of the companies this company's own investors also back.
- Arch Venture Partners
- Backed 3 companies this company's investors also back
- Co-invested 5 times with 1 of this company's investors
- Has joined rounds of over $150M (10 on record)
- Invests in Life sciences
- 6 new companies dated in the last 12 months, latest Jun 24, 2026
- ARTIS
- Backed 2 companies this company's investors also back
- Co-invested 2 times with 1 of this company's investors
- Invests in Life sciences
- 1 new company dated in the last 12 months, latest Aug 27, 2026
- Led 0% of 9 rounds whose lead is known
- Khosla Ventures, LLC
- Backed 2 companies this company's investors also back
- Co-invested 2 times with 1 of this company's investors
- Has joined rounds of over $150M (9 on record)
- Invests in Life sciences
- 24 new companies dated in the last 12 months, latest Sep 30, 2026
+5 more comparable investors
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Broader fit
0 firmsFirms that co-invest repeatedly with this company's investors and dated a new company in the last 12 months.
No other firm co-invests repeatedly with this company's investors on record.
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Catalio Capital Management, LP · the firm's card prints no outcome · read Sep 30, 2026 cataliocapital.com“AdvanCell”
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Aaron Pickett Executive Officer sec.gov
- Philina Lee Executive Officer/Director sec.gov
- Kevin Cameron Director Fact
- Christopher Gagliardi Director Fact
- Andrew Adamovich Director Fact
Timeline
- Jul 16, 2026AdvanCell, Inc. filed Form D: $218,333,294 sold of $315,000,000, BiotechnologyForm D filed Fact Form D
Evidence
Every observation on this company
- Entity type: Corporation Jul 16, 2026 Fact Form D
- Form D industry group: Biotechnology Jul 16, 2026 Fact Form D
- Amendment: false Jul 16, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Jul 16, 2026 Fact Form D
- Incorporated: withinFiveYears Jul 16, 2026 Fact Form D
- Jurisdiction: Delaware Jul 16, 2026 Fact Form D
- Amount sold (Form D): $218M Jul 16, 2026 Fact Form D
- Offering amount (Form D): $315M Jul 16, 2026 Fact Form D
- Exemptions: 06b Jul 16, 2026 Fact Form D
- First sale: 2026-06-30 Jul 16, 2026 Fact Form D
- Investors (Form D): 41 Jul 16, 2026 Fact Form D
- Minimum investment (Form D): 0 Jul 16, 2026 Fact Form D
- Securities offered: equity Jul 16, 2026 Fact Form D
- Office address: Jul 16, 2026 Fact Form D
- Listed on portfolio page: Sep 30, 2026 Fact
- Listed on portfolio page: Sep 16, 2026 Fact
- Listed on portfolio page: Sep 15, 2026 Fact
- Year of incorporation: 2026 Jul 16, 2026 Fact Form D
Relationships across DFX
on 1 other DFX graph
AdvanCell is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Form D filed2026-07-16source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.